Gut Microbiota Response to Glucokinase Activators in Obese and Diabetic Mice

16S-rRNA gene sequencing data from fecal samples of high-fat diet-induced obese and type 2 diabetic mice treated with dorzagliatin or TTP399 for four weeks. The dataset, authored by Lanyu Gao and last updated in March 2026, likely contains relative abundance data for bacterial genera, including short-chain fatty acid producers. Results indicate both glucokinase activators altered gut microbiota structure without significantly affecting intestinal barrier integrity.

Use Cases

• Compare gut microbiota composition changes based on treatment with different glucokinase activators (dorzagliatin vs. TTP399).
• Analyze correlations between microbial shifts and metabolic parameters mentioned in the study.
• Identify potential beneficial bacterial genera, such as short-chain fatty acid producers, associated with drug treatment.
• Investigate the dissociation between gut microbiota modulation and markers of intestinal barrier integrity and inflammation.

Strengths

• Data is associated with a specific, peer-reviewed experimental protocol involving high-fat diet mice and two drug treatments.
• Includes 16S-rRNA gene sequencing results, a standard method for profiling microbial communities.
• Shared under a permissive CC-BY-4.0 license, allowing for reuse and redistribution.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is contained in a 6.8 MB DOCX file, which may require extraction of underlying data tables.

Provenance

Source

figshare, authored by Lanyu Gao.

Collection Method

Fecal samples from mice subjected to 16S-rRNA gene sequencing.

Freshness

Last updated 2026-03-19 06:48:58; freshness should be verified.